Gamma delta T (γδT) cells are innate-like lymphocytes with strong, MHC-unrestricted cytotoxicity against cancer cells and show a promising prospect in adoptive cellular immunotherapy for various malignancies. However, the clinical outcome of commonly used Vγ9Vδ2 γδT (Vδ2 T) cells in adoptive immunotherapy for most solid tumors is limited. Here, we demonstrate that freshly isolated Vδ1 γδT (Vδ1 T) cells from human peripheral blood (PB) exhibit more potent cytotoxicity against adherent and sphere-forming human colon cancer cells than Vδ2 T cells in vitro. We also develop an optimized protocol to preferentially expand Vδ1 T cells isolated from PB of both healthy donors and colon cancer patients by in vitro short-term culture with phytohemagglutinin (PHA) and interleukin-7 (IL-7). Expanded Vδ1 T cells highly expressed cytotoxicity-related molecules, chemokine receptors and cytokines with enhanced cytolytic effect against adherent and sphere-forming colon cancer cells in a cell-to-cell contact dependent manner. In addition, PHA and IL-7 expanded Vδ1 T cells showed proliferation and survival advantage partly through an IL-2 signaling pathway. Furthermore, ex vivo expanded Vδ1 T cells also restrained the tumor growth and prolonged the tumor-burdened survival of human colon carcinoma xenografted mice. Our findings suggest that human PB Vδ1 T cells expanded by PHA and IL-7 are a promising candidate for anticancer adoptive immunotherapy for human solid tumors such as colon cancer.
Keywords: Antigens, Ags; CCSCs, colon cancer stem cells; FACS, fluorescence activated cell sorting; FCM, flow cytometry; γδT cells, gamma delta T cells; IL-7, interleukin-7; MACS, magnetic activated cell sorting; PB, peripheral blood; PHA, phytohemagglutinin; PBMCs, peripheral blood mononuclear cells; Vδ2 T cells, Vγ9Vδ2 γδT cells; Vδ1 T cells, Vδ1 γδT cells; Zol, Zoledronate.; adoptive cellular immunotherapy; cytotoxicity; human PB Vδ1 T cells; human PB Vδ2 T cells; human colon cancer.